2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 2-Oxazolidinone, 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-
• 英文别名: 4-[[3-[2-(dimethylamino)ethyl]-1H-indol-5-yl]methyl]-1,3-oxazolidin-2-one
• 化学式: C₁₆H₂₁N₃O₂
• mdl: MFCD00909189
• 分子量: 287.36
• InChiKey: ULSDMUVEXKOYBU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  21
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  57.4
• 氢给体数：
  2
• 氢受体数：
  3

ADMET

毒理性

• 在妊娠和哺乳期间的影响

◉ 母乳喂养期间使用总结：初步证据表明，佐米曲普坦在母乳中的水平较低。婴儿摄入的量很小，不太可能影响哺乳婴儿，尤其是如果婴儿年龄超过2个月。同时使用普萘洛尔可能会显著增加哺乳婴儿接收到的佐米曲普坦剂量。 ◉ 对哺乳婴儿的影响：截至修订日期，未找到相关的已发布信息。 ◉ 对泌乳和母乳的影响：截至修订日期，未找到相关的已发布信息。

◉ Summary of Use during Lactation:Preliminary evidence indicates that zolmitriptan levels in breastmilk are low. Amounts ingested by the infant are small and unlikely to affect the nursing infant, especially if the infant is older than 2 months. Concurrent use of propranolol might increase the zolmitriptan dose received by the breastfed infant substantially. ◉ Effects in Breastfed Infants:Relevant published information was not found as of the revision date. ◉ Effects on Lactation and Breastmilk:Relevant published information was not found as of the revision date.

来源:Drugs and Lactation Database (LactMed)

文献信息

• METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS
  申请人：TUFTS MEDICAL CENTER

  公开号：US20160052982A1

  公开（公告）日：2016-02-25

  The present application provides methods for preparing soluble lipidated ligand agents comprising a ligand entity and a lipid entity, and in some embodiments, provides relevant parameters of each of these components, thereby enabling appropriate selection of components to assemble active agents for any given target of interest.

  本申请提供了制备可溶性脂质化配体药剂的方法，包括配体实体和脂质实体，并在某些实施例中提供了这些组分的相关参数，从而使得能够适当选择组分来组装出针对任何感兴趣的靶点的活性药剂。
• Use of tachykinin antagonists in combination with serotonin agonists or serotonin reuptake inhibitors for the manufacture of a medicament for the treatment of allergic rhinitis
  申请人：ELI LILLY AND COMPANY

  公开号：EP0747049A1

  公开（公告）日：1996-12-11

  This invention provides methods for the treatment or amelioration of the symptoms of the common cold or allergic rhinitis which comprises administering to a mammal in need thereof a combination of a tachykinin receptor antagonist and either a serotonin agonist or a selective serotonin reuptake inhibitor. This administration may be concurrent or sequential, with either of the two activities being administered first.

  这项发明提供了治疗普通感冒或过敏性鼻炎症状的方法，包括向需要的哺乳动物施用一种缓释肽受体拮抗剂和5-羟色胺激动剂或选择性5-羟色胺再摄取抑制剂的组合。这种给药可以同时进行或顺序进行，两种活性中的任何一种都可以首先给予。
• [EN] PROCESS FOR PREPARING ZOLMITRIPTAN COMPOUNDS<br/>[FR] PROCEDE D'ELABORATION DE COMPOSES DE ZOLMITRIPTAN
  申请人：VITA LAB

  公开号：WO2004014901A1

  公开（公告）日：2004-02-19

  In particular, zolmitriptan or a pharmaceutically acceptable salt thereof, which includes a) Preparation of the diazonium salt of the aniline hydrochloride (II); followed by reduction and acidification to give hydrazine (III); b) In situ Reaction of the hydrazine hydrochloride (III) with ?-keto-?-valerolactone, to give the hydrazone (IV); c) Fischer indole synthesis of the hydrazone (IV), to give the pyranoindolone of formula (V); d) Transesterification of the pyranoindolone (V) to provide the compound (VI), in which R means a straight or branched C1-C4 alkyl; e) Conversion of the hydroxyl group of the compound (VI) into dimethylamino to give the indolecarboxylate (VII), in which R means a straight or branched C1-C4 alkyl; f) Saponification of the 2-carboalkoxy group of the compound (VII), to provide indolecarboxylic acid (VIII); g) Decarboxylation of the indolecarboxylic acid (VIII), to provide zolmitriptan and, eventually, to provide a pharmaceutically acceptable salt thereof.

  特别是左米曲坦或其药学上可接受的盐，包括：a）制备苯胺盐酸盐（II）的重氮盐，随后还原和酸化以得到肼（III）; b）肼盐酸盐（III）与?-酮-?-戊内酯原位反应，得到肼酮（IV）; c）肼酮（IV）的费舍尔吲哚合成，得到式（V）的吡喃吲哚酮; d）转酯化吡喃吲哚酮（V）以提供化合物（VI），其中R表示直链或支链C1-C4烷基; e）将化合物（VI）的羟基转化为二甲氨基以得到吲哚羧酸酯（VII），其中R表示直链或支链C1-C4烷基; f）皂化化合物（VII）的2-羧酰氧基，以提供吲哚羧酸（VIII）; g）将吲哚羧酸（VIII）脱羧，以提供左米曲坦，并最终提供其药学上可接受的盐。
• ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF ZOLMITRIPTAN
  申请人：Li Wenge

  公开号：US20100217013A1

  公开（公告）日：2010-08-26

  An enantioselective process for preparing zolmitriptan, (S)-4-[3-[2-(dimethylamine)ethyl]-1H-indol-5-yl]methyl}-2-oxazolidinone), by asymmetric hydrogenation of (Z)-2-(acetylamino)-3-[3-N,N-(dimethylamine)ethyl)-1H-indol-5-yl]-2-propenoic acid methyl ester in the presence of hydrogen and an enantioselective chiral phosphine transition metal catalyst.

  一种对左旋咪替丹进行对映选择性制备的方法，该方法通过在氢气和对映选择性手性膦过渡金属催化剂的存在下，对(Z)-2-(乙酰氨基)-3-[3-N,N-(二甲基氨基)乙基]-1H-吲哚-5-基]-2-丙烯酸甲酯进行不对称氢化反应。反应产物为(S)-4-[3-[2-(二甲基氨基)乙基]-1H-吲哚-5-基]甲基}-2-噁唑烷酮。
• PROCESS FOR PREPARATION OF ZOLMITRIPTAN
  申请人：Gurjar Mukund Keshav

  公开号：US20140228582A1

  公开（公告）日：2014-08-14

  The present invention provides a convenient and industrially viable process for preparation of Zolmitriptan (I) having desired purity. The invention specifically relates to a method for isolating (S)-4-(4-hydrazinobenzyl)-1,3-oxazolidin-2-one hydrochloride (IIIa) of desired purity by separating the undesired inorganic side products such as stannous hydroxide by manipulation of pH at different stages and finally treating with N,N-dimethylamino butyraldehyde diethyl acetal in an acidic medium to provide Zolmitriptan (I) conforming to regulatory specifications.

  本发明提供了一种方便且在工业上可行的制备所需纯度Zolmitriptan（I）的方法。本发明具体涉及一种通过在不同阶段操作pH来分离不需要的无机副产物，例如氢氧化锡，最终在酸性介质中处理N，N-二甲基氨基丁醛二乙醚酯，以提供符合监管规范的Zolmitriptan（I）的方法。同时，本发明还提供了一种分离所述纯度所需的（S）-4-（4-肼基苯基）-1,3-噁唑烷-2-酮盐酸盐（IIIa）的方法。